secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2026-10-14T12:43:34+00:00
Accession:  0001437749-26-032601
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Pulse Biosciences, Clayman Thyroid Center announce nPulse Vybrance commercial and clinical partnership
--------------------------------------------------------------------------------

- Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida is now treating patients with the nPulse Vybrance Percutaneous Electrode System for symptomatic benign thyroid nodules.
- Clayman is the only site in the Tampa Bay Area offering nPulse technology; the rollout is part of Pulse Biosciences' controlled market development strategy.
- Clinical collaboration covers real-world outcomes collection and formal studies of nsPFA energy in benign thyroid nodule treatment; no financial terms disclosed.
- CEO Paul LaViolette said Clayman is one of the largest thyroid surgery centers nationally with significant regional and national referral patterns.
- Vybrance delivers nonthermal nanosecond pulsed field ablation under ultrasound guidance; patients go home same day and symptoms typically ease within weeks.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774926032601/0001437749-26-032601-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774926032601/plse20261013_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-032601

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer